Using X-rays, digital tomosynthesis builds a three-dimensional image of the breast. Although digital tomosynthesis has received approval from the U.S. Food and Drug Administration, it is not yet regarded as the gold standard for breast cancer screening.
Similar to how a chest CT scan differs from a regular chest X-ray, digital tomosynthesis of the breast differs from a typical mammography. Or consider the differences between a circle and a ball. One is three-dimensional, the other is flat.
The Global Digital Tomosynthesis market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
Agfa announced the launch of their digital tomosynthesis product, which provides a quick, affordable, and low-dose method to distinguish anatomical overlap in a range of applications.
Digital tomosynthesis, powered by MUSICA, automatically generates 3D reconstructions with ideal contrast and consistent quality across slices and images.
The digital tomosynthesis solution can provide therapeutic value in a variety of fields, including orthopaedics (for the detection of microfractures, weight-bearing tests, etc.), pulmonology (nodules, airway lesions, etc.), and urology.
It provides accurate results that enhance the patient’s experience and success by fusing the benefits of multi-slice reconstruction with the low dose and quick workflow of general radiography.
The DR 800’s inclusion of digital tomosynthesis gives them another imaging option that expedites diagnosis. It reveals details that conventional X-ray imaging might not pick up. However, it can be accomplished without removing the patient from the X-ray area.
Digital tomosynthesis from Agfa produces insightful results from buried depths. This kind of customer-focused innovation satisfies the requirement for radiology to develop clever, effective, and constantly developing solutions that bring genuine clinical value and improve patient comfort and pleasure.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.